Literature DB >> 27091001

Cellular models for Parkinson's disease.

Björn H Falkenburger1,2, Theodora Saridaki3, Elisabeth Dinter3.   

Abstract

Developing new therapeutic strategies for Parkinson's disease requires cellular models. Current models reproduce the two most salient changes found in the brains of patients with Parkinson's disease: The degeneration of dopaminergic neurons and the existence of protein aggregates consisting mainly of α-synuclein. Cultured cells offer many advantages over studying Parkinson's disease directly in patients or in animal models. At the same time, the choice of a specific cellular model entails the requirement to focus on one aspect of the disease while ignoring others. This article is intended for researchers planning to use cellular models for their studies. It describes for commonly used cell types the aspects of Parkinson's disease they model along with technical advantages and disadvantages. It might also be helpful for researchers from other fields consulting literature on cellular models of Parkinson's disease. Important models for the study of dopaminergic neuron degeneration include Lund human mesencephalic cells and primary neurons, and a case is made for the use of non-dopaminergic cells to model pathogenesis of non-motor symptoms of Parkinson's disease. With regard to α-synuclein aggregates, this article describes strategies to induce and measure aggregates with a focus on fluorescent techniques. Cellular models reproduce the two most salient changes of Parkinson's disease, the degeneration of dopaminergic neurons and the existence of α-synuclein aggregates. This article is intended for researchers planning to use cellular models for their studies. It describes for commonly used cell types and treatments the aspects of Parkinson's disease they model along with technical advantages and disadvantages. Furthermore, this article describes strategies to induce and measure aggregates with a focus on fluorescent techniques. This article is part of a special issue on Parkinson disease.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  Dementia with Lewy bodies; FRET; non-motor symptoms

Mesh:

Substances:

Year:  2016        PMID: 27091001     DOI: 10.1111/jnc.13618

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  27 in total

Review 1.  N-terminal fusion potentiates α-synuclein secretion [correction].

Authors:  Björn H Falkenburger
Journal:  Cell Mol Neurobiol       Date:  2018-10-04       Impact factor: 5.046

2.  Metabolomics Analyses from Tissues in Parkinson's Disease.

Authors:  Fatema Bhinderwala; Shulei Lei; Jade Woods; Jordan Rose; Darrell D Marshall; Eli Riekeberg; Aline De Lima Leite; Martha Morton; Eric D Dodds; Rodrigo Franco; Robert Powers
Journal:  Methods Mol Biol       Date:  2019

Review 3.  Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases.

Authors:  Ana B Ramos-Hryb; Francis L Pazini; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

Review 4.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

Review 5.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

6.  Hyperoside Reduces Rotenone-induced Neuronal Injury by Suppressing Autophagy.

Authors:  Huijie Fan; Yanrong Li; Mengying Sun; Wushuai Xiao; Lijuan Song; Qing Wang; Bo Zhang; Jiezhong Yu; Xiaoming Jin; Cungen Ma; Zhi Chai
Journal:  Neurochem Res       Date:  2021-08-20       Impact factor: 3.996

Review 7.  Parkinson's disease and microRNAs - Lessons from model organisms and human studies.

Authors:  Brian Evans; Howard A Furlong; Alexandre de Lencastre
Journal:  Exp Gerontol       Date:  2021-10-08       Impact factor: 4.032

Review 8.  Coenzyme Q10 effects in neurological diseases.

Authors:  H Rauchová
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

9.  The long non-coding RNA Cerox1 is a post transcriptional regulator of mitochondrial complex I catalytic activity.

Authors:  Tamara M Sirey; Kenny Roberts; Wilfried Haerty; Oscar Bedoya-Reina; Sebastian Rogatti-Granados; Jennifer Y Tan; Nick Li; Lisa C Heather; Roderick N Carter; Sarah Cooper; Andrew J Finch; Jimi Wills; Nicholas M Morton; Ana Claudia Marques; Chris P Ponting
Journal:  Elife       Date:  2019-05-02       Impact factor: 8.140

10.  Stable expression of the human dopamine transporter in N27 cells as an in vitro model for dopamine cell trafficking and metabolism.

Authors:  B S Cagle; M L Sturgeon; J B O'Brien; J C Wilkinson; R A Cornell; D L Roman; J A Doorn
Journal:  Toxicol In Vitro       Date:  2021-07-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.